Creation Process
The creation process of a technical file for medical devices under the EU Medical Device Regulation (MDR) begins during the initial design and development phase and proceeds iteratively through verification, validation, and conformity assessment to ensure compliance with general safety and performance requirements (GSPRs).[23] This methodology aligns with the V-model approach, where design inputs are defined at the outset, translated into outputs, and systematically verified against regulatory standards before final compilation and submission for approval.[23] The process emphasizes traceability, risk integration, and objective evidence to demonstrate that the device meets the GSPRs as outlined in MDR Annex I, with supporting evidence compiled in accordance with Annexes II and III.[24]
The first step involves gathering design inputs and outputs, starting with the development of a design and development plan that captures user requirements specifications (URS) and functional requirements specifications (FRS).[23] These inputs, derived from intended use, user needs, and regulatory demands, are translated by research and development (R&D) teams into tangible design outputs such as device specifications, component details, and manufacturing processes.[23] Concurrently, risk assessments are conducted per MDR Annex I, Section 3, identifying hazards, estimating risks, and implementing mitigation measures linked to the FRS and GSPRs.[23] This phase includes iterative design reviews to approve outputs and ensure alignment, with documentation forming the core of the design history file (DHF) for traceability.[23]
Following risk-integrated design, test reports are compiled from pre-clinical and clinical verification and validation activities.[23] Verification confirms that design outputs meet input requirements through methods like bench testing or software validation, while validation ensures the device performs as intended in simulated or actual use scenarios.[23] These reports, along with evidence of conformity to harmonized standards (e.g., ISO 14971 for risk management), are gathered to substantiate GSPR fulfillment, with quantitative data such as performance metrics included only where they establish safety and efficacy.[23] For higher-risk devices (Class IIa, IIb, III), clinical evaluation reports per MDR Article 61 are integrated, drawing from equivalence data or post-market clinical follow-up plans if applicable.[25]
Cross-functional teams are essential throughout, with R&D leading design and testing, quality assurance (QA) overseeing risk documentation and process controls, and regulatory affairs ensuring MDR alignment and traceability matrices.[23] Collaboration occurs via structured reviews, where teams verify that all elements link back to GSPRs, preventing gaps in evidence.[23]
The final compilation indexes all documents into a structured format, often following the International Medical Device Regulators Forum (IMDRF) Summary Technical Documentation (STED) template for clarity and auditability.[23] This includes a table of contents with hyperlinks, sections on device description, manufacturing information, and benefit-risk analysis, ensuring the file is searchable and unambiguous.[23] Upon internal review by the regulatory compliance officer (MDR Article 15), the technical file is submitted to a notified body for conformity assessment (Annexes IX–XI), leading to certification if compliant.[23]
Best practices incorporate electronic quality management system (eQMS) software to manage version control, track changes via audit trails, and apply electronic signatures for approvals, facilitating secure collaboration and reducing errors in multi-site teams.[23] These tools ensure documents remain current through the approval process, with automated traceability supporting efficient notified body reviews.[23]
Updates and Retention Requirements
Technical files for medical devices under the EU Medical Device Regulation (MDR) must be updated throughout the product lifecycle to reflect evolving evidence of safety and performance. Updates are triggered by design or manufacturing changes, adverse events or incidents reported through vigilance systems, and regulatory developments such as revisions to harmonized standards or common specifications.[3] These updates integrate post-market surveillance (PMS) and post-market clinical follow-up (PMCF) data, including periodic safety update reports (PSURs), to reassess benefit-risk profiles and revise elements like risk management and clinical evaluations.[3] PSURs and related technical file updates for Class III and implantable Class IIb devices occur at least annually; for non-implantable Class IIb devices, at least biennially; for Class IIa devices, at least biennially (or triennially for non-active/non-measuring devices without medicinal substances), with immediate revisions for significant changes that could impact safety or performance.[3][26] Manufacturers are required to maintain version history tracking within their quality management systems (QMS) to document these revisions, ensuring traceability and justification for each modification.[3]
Retention requirements ensure long-term accountability and facilitate regulatory oversight. Under Article 10(8) of the MDR, technical files must be kept available to competent authorities and notified bodies for at least 10 years after the last device is placed on the market, extending to 15 years for implantable devices.[3] If the expected device lifetime is shorter than these periods, retention shall cover at least the device lifetime; if longer, the MDR minimums (10 or 15 years) apply, as guided by the Medical Device Coordination Group (MDCG).[3][26] Upon manufacturer cessation or bankruptcy, files must be transferred to an authorized representative or relevant authority to maintain continuity.[3] Digital formats are encouraged to support searchable access while preserving integrity.
To ensure audit readiness, technical files must be organized, verifiable, and readily accessible for inspections by notified bodies or authorities, often within specified timelines such as immediate provision or up to 15 days.[3] Confidentiality controls, embedded in the QMS, restrict access to authorized personnel and protect sensitive information during reviews, balancing transparency with proprietary safeguards.[3] This preparation includes cross-referencing core components like clinical evaluations, which may require revision based on new PMS data.[3]